Addressing Barriers to Statins

What is statin intolerance?³  

According to the National Lipid Association, statin intolerance is defined as one or more adverse effects associated with statin therapy, which resolves or improves with dose reduction or discontinuation, and can be classified as complete inability to tolerate any dose of a statin or partial intolerance, with inability to tolerate the dose necessary to achieve the patient-specific therapeutic objective. To classify a patient as having statin intolerance, a minimum of two statins should have been attempted, including at least one at the lowest approved daily dosage. 

Complete – Inability to tolerate any dose or regimen of a statin.  

Partial – Ability to tolerate a lower dose of statin that is required to achieve the desired therapeutic objective.  

Confirming Statin Intolerance (Assessment Prior to Classification)2,3 

Before confirming statin intolerance, it is recommended to evaluate for potentially reversible or contributing factors that may explain muscle symptoms or other adverse effects. These factors should be addressed when possible prior to classifying a patient as statin intolerant. 

Potential reversible factors include: 

• Untreated or undertreated hypothyroidism 

• Vitamin D deficiency 

• Drug–drug interactions that increase statin exposure 

• Recent vigorous or unaccustomed physical activity 
• Acute illness or metabolic abnormalities 

Statin intolerance should not be classified based on a single statin exposure without appropriate evaluation and reassessment. 

How should I react when a patient says they cannot tolerate a statin? 

When a patient reports statin intolerance, it is important to pause before labeling the patient as statin intolerant and to clarify what “intolerance” means from the patient’s and/or prescriber’s perspective. Many patients who report intolerance can still tolerate some form of statin therapy, particularly when alternative agents, dosing strategies, or intensities are considered. 

If a patient reports intolerance after exposure only to moderate‑ or high‑intensity statins, recognize that low‑intensity statins or reduced‑frequency dosing regimens can still provide meaningful cardiovascular benefit and should be considered before discontinuing statin therapy altogether. 

Best practices for addressing reported statin intolerance include: 

• Review statin exposure history 

• • Examine prescription claims or confirm with the patient or prescriber how many statins have been tried, at what doses, and for how long. 

• • If the patient has switched between multiple statins, clarify the reason(s) for each change (e.g., muscle symptoms, laboratory abnormalities, patient concern, or prescriber preference). 

• Normalize and educate 

• • Explain that experiencing muscle pain or other adverse effects with one statin does not mean that all statins will cause the same reaction. 

• • Reinforce that statin intolerance exists on a spectrum, and many patients can tolerate an alternative statin, lower dose, or different regimen. 

• Propose evidence‑based strategies to improve tolerability 

• • Trial a lower dose of the same statin, with gradual titration as tolerated. 

• • Switch to an alternative statin, particularly those that are less lipophilic (e.g., pravastatin or rosuvastatin), which may be less likely to cause muscle symptoms. 

• • Consider intermittent dosing using long half‑life statins (e.g., rosuvastatin dosed 2–3 times per week) in patients unable to tolerate daily dosing. 

Rechallenge and Reassessment Strategy^{2, 3, 5}

True statin intolerance is supported when adverse symptoms: 

• Occur during statin therapy 

• Improve or resolve with statin dose reduction or discontinuation 

• Return with statin rechallenge 

Rechallenge with an alternative statin, a lower dose, or an altered dosing schedule is recommended when clinically appropriate. Permanent discontinuation of statin therapy should be avoided whenever possible without structured reassessment. 

Statin Therapy Approach  

 

 

How should I respond when a patient says they do not need a statin because they do not have high cholesterol?  

Reference benefits of statin therapy related to the patient’s specific condition(s). One recommended approach is to:  

• Verify the medical condition that prompted the need for statin initiation (e.g., diabetes, CAD, CVD, stroke/TIA).  

• Explain how that condition raises their risk for serious complications.   

• • Example: “Your [insert specific condition] increases your risk for serious complications in the future, such as a heart attack or a stroke. Even if your cholesterol levels are not high right now, there is still a risk that cholesterol will build up over time and potentially cause a blockage in an artery. Statin therapy is recommended for people with [insert specific condition] to prevent or lessen the risk of those serious events happening to you.”  

Calculating a patient’s ASCVD risk:¹

The 2026 ACC/AHA Dyslipidemia Guideline recommends using the PREVENT-ASCVD outcome-specific equations to estimate ASCVD risk to inform management decisions for lipid-lowering therapy (LLT) among adults without known ASCVD or subclinical atherosclerosis with an LDL-C between 70–189 mg/dL. 

PREVENT‑ASCVD 10‑year risk categories: 

• Low: <3% 

• Borderline: 3% to <5% 

• Intermediate: 5% to <10% 

• High: ≥10% 

Lipid-lowering‑ therapy (LLT) is recommended for patients at intermediate and high risk, reasonable for borderline risk, and may be considered in low risk‑ patients with high LDLC or elevated 30‑ year ASCVD risk. Patients with severe hypercholesterolemia, diabetes, chronic kidney disease, or HIV should receive lipid-lowering therapy regardless of estimated risk. 

Which statins and doses are considered high-intensity, moderate-intensity and low-intensity?²  

High-, Moderate- and Low-Intensity Statin Therapy 

	High-Intensity	Moderate-Intensity	Low-Intensity
Expected % LDL-C Reduction†	≥50%	30%-49%	<30%
Preferred Statins	Atorvastatin (40 mg) 80 mg  Rosuvastatin 20 mg (40 mg)	Atorvastatin 10 mg (20 mg)   Rosuvastatin (5 mg) 10 mg
Other Statins		Fluvastatin XL 80 mg    Fluvastatin 40 mg BID    Lovastatin 40 mg (80 mg)  Pitavastatin 1, 2, 4 mg   Pravastatin 40 mg (80 mg)    Simvastatin 20, 40 mgǂ	Fluvastatin 20, 40 mg    Lovastatin 20 mg  Pravastatin 10, 20 mg   Simvastatin 10 mg

Expected percentage LDL-C reductions with atorvastatin, rosuvastatin, and simvastatin were estimated using the median reduction in LDL-C from the VOY-AGER database. Reductions in LDL-C for other statins (fluvastatin, lovastatin, pitavastatin, and pravastatin) were identified according to FDA-approved product labeling in adults with hyperlipidemia, primary hypercholesterolemia, and mixed dyslipidemia. Boldface type indicates specific statins and doses that were evaluated in placebo-controlled RCTs evaluating ASCVD event lowering, and the Cholesterol Treatment Trialists’ 2010 meta-analysis. These RCTs demonstrated a reduction in major ASCVD events. Modified with permission from Grundy et al. Copyright 2018 American Heart Association, Inc. and American College of Cardiology Foundation. 

*Expected percentage reductions are estimates from data across large populations. Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice owing to a high degree of heterogeneity seen with LDL-C–lowering medications. 

†Expected LDL-C lowering with the dosage listed below each intensity. 

‡Although simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin80 mg or titration to 80 mg is not recommended by the FDA because of the increased risk of myopathy, including rhabdomyolysis. 

BID indicates twice daily; FDA, US Food and Drug Administration; LDL-C, low-density lipoprotein-cholesterol; RCT, randomized controlled trial; and XL, ex-tended release. 

 Pharmacokinetic Properties of Statin Medications²

	Absorption		Distribution		Metabolism			Elimination
	Bio-availability (%)	Tmax (h)	Protein Binding (%)	Lipophilicity (log P)	CYP Hepatic Enzyme	Pro-drug	Active Metabolite	Renal Excretion (%)	T1/2 (hr)
Atorvastatin	14	1-2	≥98	Yes, 4.1	3A4	No	Yes	<2	14
Fluvastatin	24	<1	98	Yes, 3.2	2C9 (2C8, 3A4 minor)	No	No	5	3
Lovastatin	<5	2-4	≥95	Yes, 4.3	3A4	Yes	Yes	10	2-3
Pitavastatin	43-51	1	99	Yes, 1.5	2C9 (2C8 minor)	No	No	15	12
Pravastatin	17	1-1.5	50	No, -0.2	None	No	No	20	1.8
Rosuvastatin	20	3-5	88	No, -0.3	2C9	No	Minimal	10	19
Simvastatin	<5	4	95	Yes, 4.7	3A4	Yes	Yes	13	2

Atorvastatin, lovastatin, and simvastatin are P-glycoprotein substrates and may be subject to certain drug–drug interactions. Modified with permission from Wiggins et al. © 2016 American Heart Association, Inc. 

CYP indicates cytochrome P450; h, hour; Tmax, time until maximum serum concentration achieved; and t1/2, drug half-life. 

Best Practices   

When talking with the prescriber:  

• Use clinical guidelines and supporting evidence provided in the TIP overview.  

• Have your recommendation ready, “Based on the other medications the patient is taking, I’d like to recommend (name of medication).”  
• Keep the patient’s health at the center of the conversation−be prepared to defend your recommendation!   

When talking with the patient:  

• Discuss the benefits of using the suggested medication.  

• Approach this as an “opportunity to improve your drug therapy” rather than a chance to “fix a mistake the prescriber has made.”   
• Communicate the change to the patient after receiving the prescriber’s approval, “Here is a new medication your doctor has ordered for you”  
   

Other Supporting Documentation for Statin Initiation  

1. JUPITER Trial - For those treated with a statin vs those not treated with a statin, results showed:⁶

• • 44% reduction in the trial primary end point of all vascular events (P<0.00001)  

• • 54% reduction in myocardial infarction (P=0.0002)  

• • 48% reduction in stroke (P=0.002)  

• • 46% reduction in need for arterial revascularization (P<0.001)  

• • 20% reduction in all-cause mortality (P=0.02)  

2. Pleiotropic effects of statins include:⁴

• • Improvement of endothelial dysfunction  

• • Increased bioavailability of nitric oxide  

• • Antioxidant effects  

• • Inhibition of inflammatory responses   

• • Stabilization of atherosclerotic plaques   

 

 

Resources:   

1. American Heart Association. PREVENT™ calculator: predicting risk of cardiovascular disease events. https://professional.heart.org/en/guidelines-and-statements/prevent-calculator. 
2. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published online March 13, 2026. doi:10.1161/CIR.0000000000001423. 
   https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423. 
   
   
3. Cheeley MK, Saseen JJ, Agarwala A, et al. National Lipid Association scientific statement on statin intolerance: a new definition and key considerations for atherosclerotic cardiovascular disease risk reduction in the statin‑intolerant patient. J Clin Lipidol. 2022;16(4):361‑375. doi:10.1016/j.jacl.2022.05.002 
   https://www.lipidjournal.com/article/S1933-2874(22)00167-2/fulltext
4. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 suppl 1):III‑39–III‑43. doi:10.1161/01.CIR.0000131517.20177.5A 
   https://www.ahajournals.org/doi/10.1161/01.CIR.0000131517.20177.5A
5. Fitchett DH, et al. Statin intolerance. Circulation. 2015;131(13):e389-e391. doi:10.1161/CIR.0000000000000177 
   http://circ.ahajournals.org/content/131/13/e389#T4.
6. Ridker PM. The JUPITER trial: results and implications for prevention. Circ Cardiovasc Qual Outcomes. 2009;2(3):279-285. doi:10.1161/CIRCOUTCOMES.109.868299 
   https://www.ahajournals.org/doi/10.1161/circoutcomes.109.868299